MTEX Mannatech Inc.

Mannatech Australasia Launches Highest Grade Aloe Product in the World, Manapol Powder

Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, recently launched its most legendary ingredient, Manapol® powder, to its Australasian market. Manapol is the highest quality aloe vera gel extract in the world.

Manapol powder is a pure, premium, 100 percent aloe vera gel extract that is abundant in acetylated, mannose-rich polysaccharides, or acemannans. The acemannans in Manapol powder have a guaranteed molecular weight of more than one million Daltons1, testing the highest of any other aloe gel extract. As the most cutting-edge Glyconutritional product available, Manapol powder supports cellular communication and may provide gastrointestinal benefits.

“We are thrilled to provide our most potent ingredient as a stand-alone product in our Australasian market,” said Mannatech’s Regional President of EMEAA, Christopher Simons. “Manapol is our core technology at Mannatech, and I know that our Australian, New Zealand and Singaporean Associates are pleased to have access to the world’s highest quality aloe vera product to help improve the health and wellness of everyone around them.”

For more than 20 years, Manapol powder has been an essential ingredient in other Mannatech products. Mannatech’s Advanced Ambrotose® product and Ambrotose® complex are among the company’s top-selling products containing the aloe gel extract, and are known for their immune and gastrointestinal benefits. Recently Mannatech announced it has secured its continuing source of premium Manapol powder with an exclusive deal with Natural Aloe Costa Rica. With this agreement, Mannatech provides its customers with transparency about where exactly the aloe in its products comes from.

To begin changing your life and the lives of those around you, please visit Mannatech.com.

About Mannatech

Mannatech, Incorporated, offers a profound wellness experience that makes a difference in the lives of people across the world. Through its innovative Glyconutrition products, Mannatech changes lives, providing an unprecedented level of natural wellness, freedom and purpose. With more than 20 years of experience and operations in more than 26 markets, Mannatech is committed to changing lives. For more information, visit Mannatech.com.

Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

1 The Chemical Abstract Society (CAS) has defined acemannan as requiring a molecular weight of one million Daltons or more.

EN
26/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mannatech Inc.

 PRESS RELEASE

Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of ...

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the “Board”) appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominat...

 PRESS RELEASE

Mannatech Reports Financial Results for Third Quarter 2024

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease...

 PRESS RELEASE

Mannatech Reports Financial Results for Second Quarter 2024

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease ...

 PRESS RELEASE

Mannatech Announces Appointment of James Clavijo as Chief Financial Of...

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ: LVGN), Guided Therapeutics (OTC: GTHP), Aeterna Zentaris (NASDAQ: AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical c...

 PRESS RELEASE

Mannatech Reports Financial Results for First Quarter 2024

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2024. First Quarter Highlights Net sales for the quarter ended March 31, 2024 were $29.4 million, as compared to $34.1 million for the same period in 2023, a decrease of $4.7 million, or 13.8%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $3.9 million, or 11.3%, and unfavorable foreign exchange caused a $0.8 million decrease in GAAP net sales as compar...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch